LTbetaR

N/A

Report date: 2024/11/07 20:00:06

Base Information

Drug NameLTbetaR

Drug Alias NameLtbRPF-07329640

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibody

Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 3

TargetsTumor necrosis factor receptor superfamily member 3

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5]

Other Information

ATC CodeN/A